PMID- 21431945
OWN - NLM
STAT- MEDLINE
DCOM- 20121207
LR  - 20211020
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Linking)
VI  - 32
IP  - 6
DP  - 2012 Jun
TI  - Role of matrix metalloproteinase-3 (MMP-3) and magnetic resonance imaging of 
      sacroiliitis in assessing disease activity in ankylosing spondylitis.
PG  - 1711-20
LID - 10.1007/s00296-011-1852-8 [doi]
AB  - The objective of this study is to evaluate the role of MMP-3 and MRI in assessing 
      disease activity in sacroiliac joints of AS patients in comparison to the 
      conventional measures Bath Ankylosing Spondylitis Disease Activity Index 
      (BASDAI), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). 
      Serum MMP-3 was measured in 30 patients who fulfilled the modified New York 
      criteria for AS and in ten healthy volunteers. AS patients were categorized into 
      those having high or low MMP-3 according to a cut-off value = 7.1 ng/ml. MRI of 
      the sacroiliac joints (SIJs) was performed on all patients. SIJs were evaluated 
      for enhancement and subchondral bone marrow edema. Results of MMP-3 and findings 
      on MRI were correlated with multiple clinical parameters including BASDAI, ESR 
      and CRP. Serum MMP-3 was significantly elevated in AS patients with active 
      disease. Elevated MMP-3 levels were significantly associated with high BASDAI 
      (P = 0.046), but not with ESR or CRP. MRI showed bone marrow edema and 
      enhancement of SIJs in 19/30 patients with one patient showing enhancement only. 
      These MRI findings were not correlated with MMP-3, BASDAI, CRP or ESR. In 
      conclusion, serum MMP-3 is an objective measure reflecting clinical disease 
      activity in AS. Bone marrow edema and enhancement detected by MRI of SIJs is 
      another objective measure of disease activity, but are not correlated with MMP-3 
      or the conventional parameters as BASDAI, ESR, or CRP. Although both MMP-3 and 
      MRI can reflect disease activity in AS they seem to be unrelated, perhaps each is 
      reflecting a different aspect of disease activity. MMP-3 and MRI should be 
      considered together with BASDAI in assessing disease activity and in guiding the 
      available recommendations for initiation of biologics in AS.
FAU - Soliman, Eiman
AU  - Soliman E
AD  - Department of Internal Medicine and Rheumatology, Faculty of Medicine, Alexandria 
      University, Alexandria, Egypt. solimaneiman@yahoo.com
FAU - Labib, W
AU  - Labib W
FAU - el-Tantawi, G
AU  - el-Tantawi G
FAU - Hamimy, A
AU  - Hamimy A
FAU - Alhadidy, A
AU  - Alhadidy A
FAU - Aldawoudy, A
AU  - Aldawoudy A
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
DEP - 20110324
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Biomarkers)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Blood Sedimentation
MH  - Bone Marrow Diseases/diagnosis/enzymology/etiology
MH  - C-Reactive Protein/analysis
MH  - Case-Control Studies
MH  - Disability Evaluation
MH  - Edema/diagnosis/enzymology/etiology
MH  - Egypt
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Predictive Value of Tests
MH  - Sacroiliac Joint/*pathology
MH  - Severity of Illness Index
MH  - Spondylitis, Ankylosing/blood/complications/*diagnosis/enzymology/pathology
MH  - Surveys and Questionnaires
MH  - Up-Regulation
MH  - Young Adult
EDAT- 2011/03/25 06:00
MHDA- 2012/12/12 06:00
CRDT- 2011/03/25 06:00
PHST- 2010/11/03 00:00 [received]
PHST- 2011/02/18 00:00 [accepted]
PHST- 2011/03/25 06:00 [entrez]
PHST- 2011/03/25 06:00 [pubmed]
PHST- 2012/12/12 06:00 [medline]
AID - 10.1007/s00296-011-1852-8 [doi]
PST - ppublish
SO  - Rheumatol Int. 2012 Jun;32(6):1711-20. doi: 10.1007/s00296-011-1852-8. Epub 2011 
      Mar 24.